An announcement from GlucoTrack (GCTK) is now available.
Glucotrack, Inc. has enhanced its Board of Directors by appointing Andrew K. Balo, a seasoned professional with a wealth of experience in the medical device sector, especially in glucose monitoring systems. Balo’s background includes pivotal roles at DexCom and St. Jude Medical, where he led regulatory, clinical, and quality initiatives. Additionally, the company has amended its bylaws to lower the quorum requirement for shareholder meetings, aiming to facilitate easier decision-making and governance.
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.
